113 related articles for article (PubMed ID: 12734680)
1. Doxorubicin activity is enhanced by hyperthermia in a model of ex vivo vascular perfusion of human colon carcinoma.
Pilati P; Mocellin S; Rossi CR; Scalerta R; Alaggio R; Giacomelli L; Geroni C; Nitti D; Lise M
World J Surg; 2003 Jun; 27(6):640-6. PubMed ID: 12734680
[TBL] [Abstract][Full Text] [Related]
2. Enhanced delivery and antitumor activity of doxorubicin using long-circulating thermosensitive liposomes containing amphipathic polyethylene glycol in combination with local hyperthermia.
Unezaki S; Maruyama K; Takahashi N; Koyama M; Yuda T; Suginaka A; Iwatsuru M
Pharm Res; 1994 Aug; 11(8):1180-5. PubMed ID: 7971721
[TBL] [Abstract][Full Text] [Related]
3. Hyperthermia-enhanced tumor accumulation and antitumor efficacy of a doxorubicin-conjugate with a novel macromolecular carrier system in mice with non-small cell lung cancer.
Oyama T; Kawamura M; Abiko T; Izumi Y; Watanabe M; Kumazawa E; Kuga H; Shiose Y; Kobayashi K
Oncol Rep; 2007 Mar; 17(3):653-9. PubMed ID: 17273747
[TBL] [Abstract][Full Text] [Related]
4. Enhanced delivery of doxorubicin to tumor by long-circulating thermosensitive liposomes and local hyperthermia.
Maruyama K; Unezaki S; Takahashi N; Iwatsuru M
Biochim Biophys Acta; 1993 Jul; 1149(2):209-16. PubMed ID: 8323940
[TBL] [Abstract][Full Text] [Related]
5. Comparative pharmacokinetics of tetrahydropyranyl-doxorubicin and doxorubicin in rat isolated lung.
Dumas M; Dubuet A; D'Athis P; Camus P; Escousse A
J Pharm Pharmacol; 1992 Jan; 44(1):58-60. PubMed ID: 1350631
[TBL] [Abstract][Full Text] [Related]
6. Role of proliferation in HER2 status predicted response to doxorubicin.
Campiglio M; Somenzi G; Olgiati C; Beretta G; Balsari A; Zaffaroni N; Valagussa P; Ménard S
Int J Cancer; 2003 Jul; 105(4):568-73. PubMed ID: 12712452
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy and microSPECT/CT imaging of 188Re-DXR-liposome in a C26 murine colon carcinoma solid tumor model.
Chang YJ; Chang CH; Yu CY; Chang TJ; Chen LC; Chen MH; Lee TW; Ting G
Nucl Med Biol; 2010 Jan; 37(1):95-104. PubMed ID: 20122674
[TBL] [Abstract][Full Text] [Related]
8. Hyperthermic isolated perfusion with low-dose tumor necrosis factor alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcomas.
Rossi CR; Mocellin S; Pilati P; Foletto M; Campana L; Quintieri L; De Salvo GL; Lise M
Ann Surg Oncol; 2005 May; 12(5):398-405. PubMed ID: 15915374
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase II alpha expression in normal, inflammatory, and neoplastic conditions of the gastric and colonic mucosa.
Fogt F; Nikulasson ST; Holden JA; Alder SA; Hallgrimsson J; Jessup MJ; O'Brien MJ; Lavin PT; Goldman H
Mod Pathol; 1997 Apr; 10(4):296-302. PubMed ID: 9110290
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model.
Tuscano JM; Martin SM; Ma Y; Zamboni W; O'Donnell RT
Clin Cancer Res; 2010 May; 16(10):2760-8. PubMed ID: 20460479
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II-induced hypertension enhanced therapeutic efficacy of liposomal doxorubicin in tumor-bearing mice.
Hattori Y; Ubukata H; Kawano K; Maitani Y
Int J Pharm; 2011 Jan; 403(1-2):178-84. PubMed ID: 20934498
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of two different delivery regimens of doxorubicin in isolated hyperthermic limb perfusion.
Pfeiffer T; Krause U; Thome U; Skorzek M; Scheulen ME
Eur J Surg Oncol; 1995 Oct; 21(5):551-4. PubMed ID: 7589605
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1.
Loadman PM; Bibby MC; Double JA; Al-Shakhaa WM; Duncan R
Clin Cancer Res; 1999 Nov; 5(11):3682-8. PubMed ID: 10589787
[TBL] [Abstract][Full Text] [Related]
14. Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas.
Amin M; Badiee A; Jaafari MR
Int J Pharm; 2013 Dec; 458(2):324-33. PubMed ID: 24148663
[TBL] [Abstract][Full Text] [Related]
15. Distribution characteristics of carboxymethylpullulan-peptide-doxorubicin conjugates in tumor-bearing rats: different sequence of peptide spacers and doxorubicin contents.
Nogusa H; Yamamoto K; Yano T; Kajiki M; Hamana H; Okuno S
Biol Pharm Bull; 2000 May; 23(5):621-6. PubMed ID: 10823676
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
Lopes de Menezes DE; Pilarski LM; Allen TM
Cancer Res; 1998 Aug; 58(15):3320-30. PubMed ID: 9699662
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, micro-SPECT/CT imaging and therapeutic efficacy of (188)Re-DXR-liposome in C26 colon carcinoma ascites mice model.
Chen LC; Chang CH; Yu CY; Chang YJ; Wu YH; Lee WC; Yeh CH; Lee TW; Ting G
Nucl Med Biol; 2008 Nov; 35(8):883-93. PubMed ID: 19026950
[TBL] [Abstract][Full Text] [Related]
18. Tissue distribution, antitumour activity and in vivo apoptosis induction by MEN10755 in nude mice.
Gonzalez-Paz O; Polizzi D; De Cesare M; Zunino F; Bigioni M; Maggi CA; Manzini S; Pratesi G
Eur J Cancer; 2001 Feb; 37(3):431-7. PubMed ID: 11239767
[TBL] [Abstract][Full Text] [Related]
19. New insight into hyperthermic intraperitoneal chemotherapy: induction of oxidative stress dramatically enhanced tumor killing in in vitro and in vivo models.
Lehmann K; Rickenbacher A; Jang JH; Oberkofler CE; Vonlanthen R; von Boehmer L; Humar B; Graf R; Gertsch P; Clavien PA
Ann Surg; 2012 Nov; 256(5):730-7; discussion 737-8. PubMed ID: 23095616
[TBL] [Abstract][Full Text] [Related]
20. Effect of repetitive administration of Doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model.
Arnold RD; Mager DE; Slack JE; Straubinger RM
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8856-65. PubMed ID: 16361575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]